The interleukin-like epithelial-to-mesenchymal transition (EMT) inducer (ILEI)/FAM3C is a member of the highly homologous FAM3 family and is essential for EMT and metastasis formation. It is upregulated in several cancers, and its altered subcellular localization strongly correlates with poor survival. However, the mechanism of ILEI action, including the structural requirements for ILEI activity, remains elusive. Here, we show that ILEI formed both monomers and covalent dimers in cancer cell lines and in tumors. Using mutational analysis and pulse-chase experiments, we found that the four ILEI cysteines, conserved throughout the FAM3 family and involved in disulfide bond formation were essential for extracellular ILEI accumulation in cultured cells. Modification of a fifth cysteine (C185), unique for ILEI, did not alter protein secretion, but completely inhibited ILEI dimerization. Wild-type ILEI monomers, but not C185A mutants, could be converted into covalent dimers extracellularly upon overexpression by intramolecular-to-intermolecular disulfide bond isomerization. Incubation of purified ILEI with cell culture medium showed that dimerization was triggered by bovine serum in a dose-and time-dependent manner. Purified ILEI dimers induced EMT and trans-well invasion of cancer cells in vitro. In contrast, ILEI monomers and the dimerizationdefective C185A mutant affected only cell motility as detected by scratch assays and cell tracking via time-lapse microscopy. Importantly, tumor cells overexpressing wild-type ILEI caused large tumors and lung metastases in nude mice, while cells overexpressing the dimerization-defective C185A mutant behaved similar to control cells. These data show that covalent ILEI self-assembly is essential for EMT induction, elevated tumor growth, and metastasis.
Introduction
Metastasis of carcinomas is the major cause of cancerrelated death [1] , yet our understanding and tools for intervention at this step of cancer pathogenesis are still very poor. The first permissive step of metastasis is the physical dissemination of cancer cells of the primary tumor. Many aspects of this process resembles epithelial-to-mesenchymal transition (EMT), a phenomenon that occurs during development [2, 3] . In cancer, this 'EMT-like' pathological process (from now on shortly EMT) transiently and reversibly converts sessile, adherent epithelial tumor cells to motile and invasive mesenchymal cells [4, 5] among others by deregulating epithelial polarity [6, 7] . Beside changes in cellular morphology, it is combined with a well-characterized switch in marker protein expression [loss of epithelial markers, for example, E-cadherin and Zonula Occludens-1 (ZO-1) and gain of mesenchymal markers, for example, vimentin, smooth muscle actin, and fibronectin] [8] . Tumor cells recruit diverse cell types into their microenvironment (e.g. endothelial cells, fibroblasts, different immune cells), which secrete EMT-inducing [1] and other tumor-promoting signals [9, 10] . Above this, cancer cells establish autocrine signaling loops that also help them to maintain EMT until they reach sites for secondary seeding [11, 12] .
One of the important secreted factors that regulate tumor progression and metastasis is interleukine-like EMT inducer (ILEI), also called FAM3C [13, 14] . It is an EMT-specific translationally regulated target of transforming growth factor beta (TGFb) being essential for EMT, tumor formation, and late events in metastasis [14] [15] [16] [17] . ILEI overexpression induces EMT in vitro and elevated tumor growth and metastasis in vivo in many tumor cell lines [14, 18] , for example, in EpC40 cells-a murine tumorigenic, but nonmetastatic mammary epithelial cell line [19, 20] . In accordance with this, RNA interference-mediated ILEI knock down (KD) inhibits invasion, EMT, and metastasis in several cancer cell models [13, 14, 17, 21, 22] . Importantly, the ILEI protein is overexpressed in many human tumors and shows elevated secretion that is histologically detectable as an altered subcellular localization of the protein [21] . Altered ILEI localization and thus, increased secretion, strongly correlates with metastasis formation and poor survival in human breast, hepatocellular, and colorectal carcinomas [14, 18, 21, 23] . A classification, however, based on differences in subcellular protein distribution seems to be challenging for routine clinical use. ILEI mRNA and protein expression levels are found so far to be prognostic only in esophageal squamous cell carcinoma [24] , most probably due to the complex post-transcriptional and post-translational regulation of its gene function [17, 21, 25] . Therefore, identification of features determinant for ILEI activity that would better translate the prognostic power of the gene into the clinics are of high importance. Recombinant ILEI has been shown to induce EMT in EpRas cells [14] , an oncogenic Ras transformed murine mammary epithelial cell line [26] , further indicating that the secreted protein is responsible for ILEI function. However, the same study stated that a reproducible procedure to generate large amounts of bioactive recombinant ILEI remains to be developed, suggesting that crucial characteristics of the active form of the protein might be still unknown.
Interleukine-like EMT inducer belongs to the FAM3 cytokine family. The four members of the family [FAM3A, B, C (=ILEI) and D] share high levels of sequence similarity. The recently resolved crystal structure of FAM3B shows that the molecule does not form the originally predicted four-helix bundle cytokine fold, but a novel b-b-a fold unique for the FAM3 family [27] . These structural studies also confirm earlier predictions that two disulfide bridges formed by the four conserved cysteines of the family stabilize protein folding of FAM3 family cytokines. These are the covalent bonds between cysteines 58 and 86 and 64 and 221 in murine and human ILEI [27] . Structural-functional studies indicate that FAM3B acts as monomer, and proteolytic processing and the presence of intact disulfide bonds are required for the proapoptotic activity of the molecule on a-and b-pancreatic islet cells [27] [28] [29] . Similarly, ILEI is proteolytically processed in the extracellular space, which is essential for its tumor-promoting function [21] . Unlike the other three FAM3 members, ILEI has an additional fifth cysteine in its sequence. Its evolutionary appearance dates to the reptiles. Although the very low sequence diversity among ILEI orthologs (80-96% identity) does not allow to clearly conclude its selective conservation, C185 is present in all higher vertebrate ILEI molecules.
In this study, we provide biochemical evidence that ILEI exists both as monomers and disulfide bondmediated dimers. The fifth, nonconserved cysteine in ILEI is important for covalent self-association. We demonstrate that only ILEI dimers are able to induce EMT and increase trans-well invasion in vitro and that covalent self-association capability of ILEI is essential for increased tumor formation and metastasis.
Results

ILEI forms covalently linked dimers via disulfide bonds
The four conserved cysteines of ILEI have been shown to be involved in the formation of two disulfide bridges within the molecule (Fig. 1A) [27] . Interestingly, in western blot analysis under nonreducing conditions ILEI was detected in three separate bands in the conditioned medium (CM) of EpRas cells (Fig. 1B) . The existence of the three ILEI bands was validated in purified secreted recombinant ILEI by western blot and silver staining of nonreducing SDS/ PAGE (Fig. 1C,D) . Mass spectrometric analysis of these three bands confirmed that each of them contained ILEI, and the 40 kDa band did not contain any other protein excluding the possibility of heterodimerisation by covalent interaction with other partners (Fig. 1E) . Thus, this indicated that (a) the band running at a lower molecular weight than the reduced protein corresponded to ILEI molecules with intramolecular disulfide bonds, as expected from structural predictions [27] , (b) the band running at the same size as the reduced sample represented the unfolded protein without disulfide bridges, and (c) the band running at a higher molecular weight of about 40 kDa contained covalent ILEI homodimers. The general validity for the existence of covalent ILEI dimers was verified in CM of a panel of murine and human cell lines of different cancer types (Fig. 1F ) and in protein extracts of human tumor xenografts (Fig. 1G ).
To show that ILEI is able to dimerize, we performed transient coexpression experiments using Cterminally 6xHis affinity and HA epitope-tagged versions of murine ILEI constructs in NIH3T3 cells. We could confirm ILEI self-association both in CM and whole-cell lysates by analyzing the coprecipitation of HA epitope-tagged ILEI after Ni-nitrilotriacetic acid (Ni-NTA) pull-down of the 6xHis tagged form (Fig. 1H) . Nonreducing SDS/PAGE of these precipitates confirmed the presence of covalent ILEI dimers (Fig. 1H, lower panel) . In CM, ILEI dimerization occurred exclusively via covalent, disulfide bondmediated interaction, since coprecipitating HA-tagged ILEI was detected only at the size of dimers (40 kDa) by an HA-specific antibody (Fig. 1H, lower left panel) . In whole-cell lysates, however, coprecipitating ILEI-HA was detected both at the size of ILEI monomers and of dimers (Fig. 1H , lower right panel). As a major difference to the secreted form, intracellular ILEI contains the propeptide. To verify if noncovalent ILEI self-association depended on the propeptide, were cut to analyze by mass spectrometry. (E) Mass spectrometric analysis of the three ILEI-specific bands of purified recombinant murine ILEI-6xHis on nonreducing SDS/PAGE. The murine recombinant ILEI protein used for sequence coverage calculation is depicted as amino acid sequence. It excludes the signal peptide and propeptide sequences and it is extended with a C-terminal tag containing a linker with a TEV cleavage site followed by six Histidines. Percentage of coverage is depicted for each analyzed bands. Identified unique peptides of the individual bands are depicted in color, highly confident peptides according to Mascot scoring marked with green and peptides with lower confidence marked in red. Post-translational modifications are marked in the sequence as follows. Carbamidomethylation of cysteines is a static modification and marked with a C, whereas oxidation of methionines is a dynamic modification marked with an O. (F) ILEI western blot analysis of CM of a panel of murine and human cancer cell lines using reducing and nonreducing SDS/PAGE conditions. The loaded amount of CM at nonreducing conditions derived from following cell numbers. 4T1, murine breast cancer (2 9 10 5 cells); CAMA-1 and CAL-85-1, human breast cancer (1.5 9 10 5 cells); MKN45, human gastric cancer (1.0 9 10 5 cells); NCI-H441 and NCI-H1993, human lung adenocarcinoma (1.0 9 10 5 cells). Lanes are from two different parts of the same gel. (G) Western blot analysis of ILEI in protein extracts of NCI-H441 and NCI-H1993 subcutaneous tumor xenografts using reducing and nonreducing SDS/PAGE conditions. Numbers for both cell lines label tumors from three different mice. Asterisk marks an unspecific cross-reacting band with the ILEI antibody. Hsp90 was used as loading control. (B-F) Arrows mark the three ILEI populations with intermolecular disulfide bonds (inter S-S), with no disulfide bonds (no S-S) and with intramolecular disulfide bonds (intra S-S) as abbreviated in panel (B). Numbers in parenthesis behind the labels reducing (red.) and nonreducing (nonred.) stand for the relative amounts of samples loaded at the two conditions. (H) Ni-NTA capture of C-terminally 6xHis and HA epitope-tagged ILEI proteins transiently coexpressed in NIH3T3 cells as detected by ILEI-and HA-specific antibodies in CM and whole-cell lysates (input). Equal loading was probed by an a-tubulin (a-tub.)-specific antibody. CM and lysates were preceded for Ni-NTA affinity capture at low salt conditions followed by western blot analysis under reducing and nonreducing conditions. HA-tagged ILEI coprecipitating with His-tagged ILEI was detected by anti-HA antibody. Efficiency of Ni-NTA capture was probed by anti-ILEI antibody. Filled arrowhead labels the size of full-length endogenous and HA-tagged ILEI without proteolytic cleavage and the processed form of the ILEI-6xHis protein. Please notice that processed 6xHis affinity-tagged ILEI runs at a molecular weight comparable to that of nonprocessed endogenous and HA epitope-tagged ILEI. Open arrowhead marks nonprocessed ILEI-6xHis. (I) Transient coexpression of C-terminally 6xHis and FLAG epitope-tagged wild-type (wt) and proteolytic cleavage-mutant (FD) ILEI proteins in HEK293 cells as detected by FLAG and His-tag-specific antibodies in CM (input). Filled and open arrowheads label the size of nonprocessed FLAG and 6xHis-tagged ILEI proteins, respectively. CM was preceded for Ni-NTA affinity capture at low salt conditions followed by western blot analysis under nonreducing conditions. FLAG-tagged ILEI coprecipitating with His-tagged ILEI was detected by anti-FLAG antibody. Efficiency of Ni-NTA capture was probed by a His-tag-specific antibody.
coprecipitation assay was performed from CM of HEK293 cells transiently coexpressing two differently tagged versions (6xHis and FLAG tags) of either wildtype ILEI (wt) or a mutant form of the molecule (FD) that is known to be impaired for proteolytic cleavage, and thus, mimics the full-length protein [21] . Although secretion levels of the FD mutant protein were much lower [21] , ILEI FD -FLAG was clearly detected both at the size of monomers and dimers in Ni-NTA precipitates of ILEI FD -6xHis, whereas processed wild-type ILEI formed only covalent dimers (Fig. 1I) , as also demonstrated above. These data highly indicate that secreted processed ILEI forms dimers exclusively through disulfide bridges. In addition, this also suggests that the ILEI propeptide that is present in the intracellular protein and cleaved off only in the extracellular space, mediates noncovalent ILEI self-interaction.
Cysteine 185 is important for ILEI dimerization
Next, we analyzed which cysteines are involved in covalent ILEI dimerization. The dimerization capability of mutant ILEI constructs bearing alanine amino acid exchanges at positions of the five cysteines of the protein was monitored after transient expression in NIH3T3 cells. Importantly, only the ILEI protein mutant in the nonconserved cysteine (C185A), but none of the molecules mutant in one of the four conserved cysteines were detected in the CM ( Fig. 2A , upper panel), indicating that the latter were essential either for secretion or for stability, most probably due to their role in protein folding. Strikingly, secreted ILEI C185A mutants failed to dimerize as analyzed by nonreducing SDS/PAGE ( Fig. 2A, lower panel) . Nevertheless, they efficiently formed intramolecular disulfide bridges. Interestingly, unfolded ILEI molecules were also not present in the CM of ILEI C185A -expressing cells, indicating that the presence of an ILEI subpopulation lacking disulfide bonds might depend on dimerization capability.
Interleukine-like EMT inducer proteins mutant in one of the conserved cysteines showed somewhat decreased cellular expression (Fig. 2B, upper panel) and failed to form monomers with two intact intramolecular disulfide bonds (Fig. 2B, lower panel) . All these mutants appeared in dimers at various molecular weights, indicating that they lost the capacity to form properly folded molecules. As an opposite, ILEI C185A accumulated majorly at the size of ILEI monomers with intact intramolecular disulfide bridges, no unfolded ILEI form, and only a faint band at the size of the high molecular weight ILEI species was present in whole-cell lysates. Pulse-chase experiments confirmed that both labeled wild-type and C185A ILEI proteins efficiently accumulated in the cells and were secreted during the chase period. The other four cysteine-mutant ILEI forms showed, however, only moderate intracellular accumulation and labeled proteins did not appear in the CM over time (Fig. 2C) .
All these data indicate that the four conserved cysteines of ILEI are crucial amino acids in the quality control for intracellular and extracellular accumulation of the protein. Thus, proper folding with two intact disulfide bonds between these residues is necessary to accumulate ILEI in the extracellular place, most probably by enabling secretion. In addition, we found cysteine 185 to be important for ILEI dimerization without affecting secretion and stability of the protein.
The accumulation of extracellular ILEI dimers depends on disulfide bond rearrangements in the extracellular space and is driven by factors present in the serum
In the above experiments, we found on the one hand that proper folding with intact disulfide bonds is necessary for ILEI to accumulate in the extracellular space. On the other hand, we observed that unfolded ILEI molecules without disulfide bridges were present in the CM of cells, but only if ILEI dimers were detected as well. Thus, we hypothesized that unfolded ILEI molecules were de novo generated in the CM and might serve as obligate intermediates for extracellular dimerization driven by disulfide bond rearrangements. To test this, we treated EpRas cells with 5,5-dithiobis(2-nitrobenzoic acid) (DTNB), a noncellpermeable, activated disulfide which inhibits extracellular thiol exchange by its reaction with free thiols [30] and monitored the accumulation of ILEI monomers and dimers in the CM. While the accumulation of properly folded monomers was not influenced, addition of DTNB inhibited the generation of the unfolded ILEI population and the accumulation of ILEI dimers (Fig. 3A) . Both started to accumulate only at a late time point when DTNB showed decreasing reactivity [31] .
Next, we aimed to characterize the dimerization of secreted ILEI. Therefore, to achieve high purity, we purified 6xHis affinity-tagged versions of murine wildtype ILEI (ILEI wt ) and its dimerization-defective derivative with the C185A mutation (ILEI CA ) from CM of stably overexpressing HEK293 cells by FPLC using Ni-NTA affinity columns. Purified ILEI wt dimerized spontaneously over time (Fig. 3B ), dimerization being accelerated at 37°C, while ILEI CA monomers remained unaffected (Fig. 3C ). Spontaneous enrichment of covalent dimers in recombinant ILEI wt was inhibited when mixed with proteins of unrelated origins, for example, bovine serum (fetal calf serum, FCS), BSA, rat IgG, and a recombinant bacterial protein ( Fig. 3D,E ). This suggests that dimerization of the purified protein might rely on protein crowding, since ILEI folding forms were stabilized in protein mixtures, which reflect more closely physiological conditions. Importantly, however, the incubation of purified ILEI wt and ILEI CA in medium containing increasing concentrations of FCS led to a dose-and time-dependent accumulation of wild-type ILEI dimers, but not of ILEI CA mutants (Fig. 3F,G) . This indicates the presence of serum factors that are essential and rate limiting for ILEI dimerization in a C185-dependent manner.
In summary, these data indicate that although ILEI dimers can probably be directly secreted, the majority of extracellular dimers may derive from covalent dimerization of secreted monomers driven by still unknown factors present in the serum. Unfolded ILEI monomers may serve as an intermediate of this rearrangement. The lack of unfolded and dimer populations in DTNB-modified and dimerization-mutant (C185A) ILEI suggests that cysteine 185 with its free thiol group may provide a metastable conformation to the monomer that is necessary for dimerization rearrangements.
Purified wild-type ILEI and ILEI dimers are efficient inducers of EMT and invasiveness in vitro, whereas the activity of ILEI C185A and ILEI monomers is restricted to cell motility Initially, recombinant ILEI has been described to induce EMT in vitro [14] . However, the same study stated that a reproducible procedure for the generation of large amounts of bioactive recombinant ILEI remains to be developed. Therefore, we sought to purify bioactive recombinant ILEI with the further aim to test if its activity depends on dimerization. For this, wild-type and dimerization-mutant ILEI proteins were purified in a large scale as described above. Both purified ILEI proteins behaved on nonreducing SDS/ PAGE as expected from our transient transfection and small-scale purification experiments (Fig. 4A) . Thus, purified ILEI wt represented a mixture of ILEI monomers and disulfide bond-mediated dimers, whereas ILEI CA contained exclusively ILEI monomers with intact disulfide bonds. To be able to separately test the activity of wild-type ILEI dimers and monomers, we further purified recombinant ILEI wt by size exclusion chromatography (SEC). We separated two ILEI populations that showed pure dimer and monomer running behavior on nonreducing SDS/PAGE (Fig. 4B) . Purified wild-type monomers served also as an additional tool to evaluate if the introduced C185A mutation had any consequence on the behavior of ILEI monomers. As a control for all functional assays, identical preparations of empty vector-transfected HEK293 cells (ctrl) were performed.
As first functional assay, purified recombinant ILEI wt , ILEI CA , ILEI dimer and monomer proteins were tested for their capacity to induce EMT in vitro.
Treatment of EpRas cells with recombinant ILEI
wt or ILEI dimers efficiently induced EMT, whereas ILEI CA and ILEI monomers had no effect (Fig. 4C ). ILEI wt and ILEI dimer-treated cells lost their cobblestone-like morphology and appeared more spindle shaped (Fig. 4C, upper panel) , which was in accordance with a switch from cortical actin localization to the appearance of actin stress fibers (Fig. 4C , lower panels). EMT was further confirmed at protein level on immunostained cells by loss of the epithelial markers E-cadherin and ZO-1, and by gain of the mesenchymal markers vimentin and fibronectin (Fig. 4C, lower panels) . As the level of secreted endogenous ILEI by EpRas cells was very low and neglectable to the amount of the supplied recombinant proteins (Fig. 4D, upper panel) , it could be excluded that endogenous ILEI would substitute for the lacking activity of supplied ILEI mutants. To exclude serum-driven isomerization of purified ILEI over time, assays were performed in medium supplemented with only 4% FCS. The dimerization status of supplied ILEI remained unaltered in the CM at experimental endpoint (Fig. 4D, lower panel) . EMT induction by ILEI wt and ILEI dimers was also verified at mRNA level by performing quantitative realtime PCR on a set of EMT marker genes (Fig. 4E ).
Next, we tested the invasion-inducing capacity of the purified ILEI proteins in trans-well invasion assays. ILEI wt protein potently triggered the in vitro invasive ability of EpRas cells in a dose-dependent manner if added as an attractant in trans-well invasion assays, whereas ILEI CA purification showed no activity (Fig. 5A) . Similarly, purified ILEI dimers, but not monomers, increased the trans-well invasion of EpRas cells (Fig. 5B) .
In in vitro wound-healing assays, however, the addition of ILEI wt had only a weak effect, whereas dimerization-mutant ILEI CA -treated EpRas cells showed a moderate, but significantly increased capacity in wound closure compared to control treatment (Fig. 5C ). The effect of purified ILEI dimers and monomers on wound healing was comparable to that of the ILEI wt and dimerization-mutant form, respectively (Fig. 5D ). These observations were not a consequence of increased cell proliferation upon treatments (Fig. 5E ). Increased motility of EpRas cells upon ILEI CA and ILEI monomer treatment was confirmed by tracking the cells via time-lapse microscopy ( Fig. 5F ). The similar behavior of dimerization-mutant ILEI and SEC-separated wild-type ILEI monomer indicate that the inability of ILEI CA in EMT induction was not due to a general inactivity of the protein caused by the mutation, but rather suggests that ILEI monomers might have a different function restricted to cell motility. In summary, we were able to purify bioactive recombinant ILEI. Above data strongly support that the function of ILEI monomers is restricted to cell motility and covalent self-association of ILEI mediated by intermolecular disulfide bond formation is essential for its function as a secreted EMT and invasion-inducing factor.
Dimerization capability of ILEI is important for elevated tumor growth and metastasis
To test how essential covalent dimerization is for the tumor-promoting activity of ILEI, we performed tumor formation and metastasis assays with the murine nonmetastatic EpC40 and the human metastatic LM2-TGL breast cancer cell lines. EpC40 cells are known to gain, LM2 cells are characterized to lose metastatic capacity upon ILEI overexpression and shRNA KD, respectively [13, 14] . First, EpC40 cells overexpressing empty vector (ctrl), wild-type (WT), and dimerization-mutant (CA) forms of C-terminally FLAG epitope-tagged murine ILEI and LM2-TGL cells expressing control (shCont) or ILEI-targeting shRNAs and being additionally transfected with empty vector (shILEI), human wild-type (WT reconst ), or dimerization-mutant (CA reconst ) ILEI-FLAG expressing constructs were generated. Tumor cells were validated for differences in ILEI expression, secretion, and dimerization capabilities by SEC-mediated detection of dimer and monomer populations (Fig. 6A,B) and by western blot analysis (Fig. 6C ). Cells were then injected in mammary fat pads, and tumor growth kinetics was compared. As it has been described earlier, wild-type ILEI overexpression in EpC40 cells accelerated tumor growth (Fig. 6D,E) [21] . Importantly, however, dimerization-mutant (CA) ILEI overexpression did not lead to significantly elevated tumor growth in these cells (Fig. 6D,E) . ILEI dimers were detected in protein extracts of wild-type (WT) tumors, but not in tumors overexpressing the dimerizationmutant (CA) protein (Fig. 6F) . Similarly, the strongly impaired tumor growth capacity of LM2 cells upon ILEI KD was efficiently restored by the reconstituted expression of wild-type, but not of dimerizationmutant ILEI (Fig. 6G,H) . Immunohistological analysis of EpC40 tumors showed a decrease in E-cadherin and an increase in vimentin expression in wild-type ILEI (WT) overexpressing tumors compared to their dimerization-mutant ILEI (CA) overexpressing and control (ctrl) counterparts (Fig. 6I) , suggesting that only wildtype ILEI-overexpressing tumor cells were able to undergo EMT in vivo.
Next, we tested the importance of ILEI dimerization on lung metastatic colonization by intravenous injection of recultivated cells from EpC40 tumors and LM2 cell derivatives. All recultivated wild-type ILEI-overexpressing EpC40 tumor cells formed large lung metastases in most of the animals, as expected, whereas dimerizationmutant ILEI-overexpressing cells behaved comparable to control nonmetastatic EpC40 cells (Fig. 7A,B) . Similarly, after intravenous injection of LM2 cell derivatives, LM2 ILEI KD cells efficiently regained metastatic capacity upon re-expression of wild-type, but not of dimerization-mutant ILEI (Fig. 7C,D) . In summary, above data strongly indicate that ILEI dimerization is essential to induce EMT, elevated tumor growth, and metastasis with a general relevance for both mouse and human breast cancer.
Discussion
In this study, we provided evidence that the ILEI/ FAM3C cytokine is present in monomers and disulfide bond-mediated covalent dimers both intracellularly as well as in its secreted form. Successful 
independent experiments. Statistical significance was calculated by one-way ANOVA and marked with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001).
production of bioactive recombinant ILEI dimers and monomers allowed us to characterize the activity of these proteins in vitro. Importantly, dimerization was essential for EMT induction and increased trans-well invasion in vitro and elevated tumor growth, EMT induction, and increased metastasis colonization in vivo.
Based on experimental data of this study we propose the following model of ILEI dimerization (Fig. 8) . After synthesis of the ILEI polypeptide protein folding can occur via two different ways. (a) The protein is stabilized as monomer via two intramolecular disulfide bonds formed between the four conserved cysteines in the molecule [27] . In this conformation, dimers might be formed via propeptidemediated noncovalent interactions. Monomers are efficiently secreted and noncovalent self-association is disrupted after proteolytic removal of the propeptide in the extracellular space. (b) Alternatively, ILEI forms covalent dimers via intermolecular disulfide bridges, where dimerization is triggered by the nonconserved cysteine at position 185 in the molecule. We have indication that the majority of these dimers is produced de novo in the extracellular space. We propose that intramolecular disulfide bonds of secreted ILEI monomers are temporally hydrolyzed generating an unfolded population that serves as an intermediate in the formation of covalent dimers after disulfide bond rearrangement. This process is triggered at least partially by unknown factors of the serum.
From our study, we cannot conclude if C185 is directly involved in disulfide bond formation in ILEI dimers. Nevertheless, our data indicate the presence of more than one S-S bridges in properly folded dimers, which can be most simply explained by a 'head-to-tail dimerization', where N-and C-terminal cysteines of the one intramolecular disulfide bond might be alternatively utilized in the formation of two intermolecular S-S bridges. DTNB, an inhibitor of extracellular thiol exchange, efficiently blocked the accumulation of ILEI dimers, suggesting that dimerization depends on the availability of free reactive cysteines. Since the lack of accumulated ILEI dimers and unfolded monomers after DTNB treatment mimicked the situation found in the CM of dimerization-mutant ILEI-overexpressing cells, we hypothesize that cysteine 185, as a free thiol residue, might be an initiator of disulfide bond rearrangements in the molecule. This reasoning is supported by a structural study of ILEI showing that the intrachain disulfide bond C64-C221 in ILEI monomers is switched to an interchain disulfide bridge in dimers and that C185 does not form any disulfide bond but is located directly in the dimer interface [32] .
Cysteine 185 is unique for ILEI and not present in the other FAM3 proteins. This was initially thought to be a distinguishing feature for all FAM3C proteins but this residue appears only in reptiles first. We do not have data if ILEI orthologs of lower vertebrates have the capability of covalent dimerization. Based on the FAM3B PANDER structure, human ILEI Cys185 is unpaired but buried by the outer strands 8 and 9 [27] . The fact that the C185A mutant seems to stabilize the monomer in its closed form indicates that the native protein need some instability to be able to dimerize. C185 might be involved in rendering to ILEI monomers a metastable conformation and/or in initiating disulfide bond isomerization maybe even through the recruitment of responsible molecules with ILEI dimerizing activity.
We found dimerization activity of FCS on purified wild-type ILEI, indicating that there are factors present in the serum that drive ILEI dimer formation. To accumulate dimers, recombinant ILEI was incubated with high FCS concentrations (16%). Accordingly, lower FCS concentrations (4%) did not lead to detectable dimerization of recombinant ILEI monomers supplied to EpRas cells for a similar period of time. This also indicates that the capacity of the serum to drive covalent dimerization is limited. It will be an exciting challenge of future work to identify the serum factor (s) responsible for ILEI dimerization and to delineate how far tumor cells or cells of the tumor stroma can contribute to the production of this or other factors that trigger the formation of covalent ILEI dimers. ) as monitored by live-cell imaging over 24 h. Statistical significance was determined by unpaired two-sided Student's t-test (A, B) , by two-way ANOVA (C, D) and by one-way ANOVA (F) and marked with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001).
Cancer-related EMT is characterized by the loss of several important epithelial phenotypes, for example, cobblestone-like morphology, apical-basal polarity, and expression of epithelial biomarkers. The increased invasive phenotype of EMT has been often positively correlated with increased migration, with both thought of as hallmarks of EMT [33] . Interestingly, we found here that ILEI dimers efficiently induced EMT and increased trans-well invasion without affecting wounding-induced cell migration. In addition, ILEI monomers had the capacity to increase cell migration in a wound closure assay, but they failed to induce EMT or trans-well invasion. These findings support the observations that EMT and elevated migration can be uncoupled [34, 35] . Considering that the two different activities were linked to two different conformations of the same protein, and both of these ILEI forms were normally produced by tumor cells, might explain why EMT and increased migration were considered as tightly linked events and simultaneously observed in TGFb-induced and ILEI-overexpressing cells [14] . Nevertheless, regulatory mechanisms that would shift the ratio of secreted ILEI dimers and monomers would probably also be able to tune invasiveness, EMT, and tumor progression in cancer.
Currently available tools did not make it possible to test, if ILEI dimers alone were sufficient for elevated tumor growth and metastasis, leaving open the question for future studies to what extent ILEI monomers might have an additive function, different from invasiveness and EMT induction, in the tumor-promoting role of ILEI.
The tools we have in hand presently are limited to objectively judge the amount of ILEI dimers and monomers. The analysis of recombinant ILEI on silver gels and western blots in parallel showed that the ILEI antibody used here detected dimers much less efficiently than monomers. Thus, there is urgent need to identify molecular regions of ILEI that are suitable epitopes for the generation of monoclonal antibodies specific for dimers, monomers and both. This will enable us to reliably determine the levels of ILEI dimers and monomers in vivo and to translate our finding and its relevance onto primary human tumors. The establishment of tools for the specific detection and targeting of covalent ILEI dimers might represent a novel and promising approach in cancer diagnostics and therapy.
Experimental procedures
Cell culture
EpRas and EpC40 cell lines are derivatives of the immortalized murine mammary epithelial cell line EpH4 and were generated and provided by Hartmut Beug [19, 20, 26] , 4T1 murine breast cancer cells were provided by him as well. EpRas and EpC40 cells and their ILEI-overexpressing derivatives were cultivated and recultivated from mouse tumors as described previously [20] . LM2-TGL cell derivative is an in vivo-selected lung metastatic subline of the MDA-MB-231 breast cancer cell line stably transfected with the TK-GFP-Luciferase reporter construct generated and provided by Joan Massagu e [36] . LM2-TGL cells and their ILEI KD and reconstituted derivatives were cultivated as described elsewhere [36] . CAL85-1, CAMA1, MKN45, NCI-H441, NCI-H1993, NIH3T3, and HEK293 cells were provided by Boehringer Ingelheim, Ingelheim am Rhein, Germany and were cultured in DMEM supplemented with 10% FCS, if not depicted otherwise. Cells were cultivated in the presence of 10%, 4%, or 1% FCS as indicated at different experiments, serum withdrawal meant the replacement of FCS by 0.1% BSA that corresponds to the BSA content of about 4% FCS.
Generation of stable cell lines expressing different shRNAs and ILEI constructs
For KD of ILEI in LM2-TGL cells, mammalian nontargeting and ILEI-targeting MISSION shRNA lentiviral transduction particles (Sigma, St Louis, MS, USA) were used according to the manufacturer's instructions. Transduced cells were selected for Puromycin resistance. ILEI expression and secretion was analyzed by western blotting. Constructs containing the full-length murine or human ILEI sequence, a linker sequence with a TEV protease cleavage site followed by a 6xHis affinity tag (ILEI-6xHis) or bearing a FLAG epitope tag were PCR-cloned into pcDNA3 using EcoRI restriction sites. ILEI constructs containing point mutations for amino acid exchange or silent mutations in shRNA-targeting sites for reconstitution were generated by the Stratagene (La Jolla, CA, USA) QuickChange in vitro site-directed mutagenesis method using pcDNA3-ILEI-6xHis and -ILEI-FLAG as templates. pcDNA3-ILEI-6xHis constructs were directly transfected into HEK293 cells using Lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA) according to the Statistical significance was determined by unpaired two-sided Student's t-test (A) and two-way ANOVA (C) and marked with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001).
manufacturer's instructions. After G418 selection, single cell clones were tested for ILEI secretion levels. Modified versions of the lentiviral expression vector pWPI with IRES-GFP and IRES-dsRed were used to generate murine and human ILEI-FLAG constructs for stable mammalian gene expression in EpC40 and LM2-TGL cells and their control and ILEI KD derivatives as described earlier [21] . Sequence fidelity and the presence of the desired mutations were confirmed by DNA sequence analysis. All infected cells were FACS sorted twice for stable GFP and dsRed expression. ILEI expression levels were analyzed on western blots using anti-ILEI and anti-FLAG antibodies.
Protein extraction from cells and tumor tissue
Cells were pelleted after harvest and lysed in PLC buffer [10% Glycerol, 5 mM Hepes (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 200 lM Na3VO4, 10 mM NaF supplemented with Complete protease inhibitor (Roche, Penzberg, Germany)] on ice for 30 min followed by centrifugation and collection of the supernatant as cleared whole-cell lysate. Tumor tissue was freshly frozen, thawed, and lysed for 30 min in PLC buffer after crushing it manually using a stick followed by centrifugation and collection of the supernatant as cleared tumor extract.
Western blot analysis
Conditioned media were collected after 24 h if not indicated separately, concentrated via ultrafiltration using mini spin filter columns MWCO 10 kDa (Merck, Darmstadt, Germany). Cells were harvested and total cell number was determined. Gel loading of CM was normalized to the concentrated volume and total cell numbers, loading of cell lysates to the total protein content (Bradford assay; BioRad, Hercules, CA, USA). Samples were prepared for SDS/PAGE using 49 loading buffer containing 200 mM TRIS pH 6.8, 8% SDS, 40% glycerol, 0.2% Bromphenol Blue without (nonreducing), or with 20% b-mercaptoethanol (reducing). Western blot analysis was performed by using anti-ILEI, 1 : 1000 [14] , anti-FLAG, 1 : 500 (Sigma), anti-HA, 1 : 500 (Sigma), anti-pentaHis, 1 : 500 (Cell Signaling Technologies, Danvers, MA, USA) anti-Hsp90, 1 : 2000 (Cell Signaling Technologies), anti-b actin (Sigma) and anti-a tubulin, 1 : 2500 (Sigma) primary antibodies and ECL detection system (GE Healthcare, Chicago, IL, USA) on a Chemidoc Touch device (Bio-Rad) followed by quantification using the IMAGE LAB software (Bio-Rad).
Ni-nitrilotriacetic acid affinity chromatography for protein interaction and enrichment NIH 3T3 and HEK293 cells were seeded onto six-well plates, transiently transfected by constructs expressing wildtype and mutant forms of 6xHis and HA or FLAG-tagged versions of ILEI using Lipofectamin 2000 (Invitrogen) according the manufacturer's instructions. Twenty-four hours after transfection, 1 mL of fresh complete medium was added and CM and cells were harvested after additional 24 h of culture. Different forms of ILEI-6xHis from CM and lysates of transiently overexpressing cells were affinity-bound to Ni-NTA superflow resins in slurry under native conditions using phosphate buffer (150 mM NaCl, 50 mM NaH 2 PO 4 , pH 6.0) supplemented with protease inhibitors and 5 and 20 mM imidazole (pH 6.0) in the capturing and washing buffers. Amount of CM and lysates of overexpressing cells loaded as input directly onto SDS/ PAGE or applied for Ni-NTA capture were normalized to total protein concentration of the whole-cell lysates. In case of CM, capture was performed in 800 lL of medium supplemented with 5 mM imidazole. For capture from wholecell lysates, lysates with a total protein content of 500 lg were used, diluted in a 1 : 1 ratio with capture buffer. After wash, samples were directly boiled in 19 SDS/PAGE loading buffer in the absence of reducing agent. Upon need, bmercaptoethanol was added to the samples as a reducing agent. Western blot analysis following reducing and nonreducing SDS/PAGE was performed using ILEI and HA or pentaHis and FLAG antibodies. In case of enrichment of different ILEI-6xHis forms, protocol was modified to buffer conditions with 500 mM NaCl content.
Mass spectrometry: sample preparation and LC-MS analysis
Gel pieces containing Coomassie-stained protein bands were cut out, destained with 100 mM NH 4 For LC-MS analysis, dried samples were reconstituted in 5 lL 30% formic acid containing 10 fmol each of four synthetic standard peptides and diluted with 40 lL mobile phase A (98% H 2 O, 2% ACN, 0.1% formic acid). Synthetic peptides [Glu1-Fribrinopeptide B -EGVNDNEEGFFSAR; M28 -TTPAVLDSDGSYFLY SK; HK0 -VLETKSLYVR; HK1 -VLETK(e-AC)SLY VR] were spiked in each sample as internal quality control for LC-MS-system stability. About 10 lL of this solution were then injected into the Dionex Ultimate 3000 nano LC-system coupled to a QExactive orbitrap mass spectrometer equipped with a nanospray ion source (Thermo Fisher Scientific, Waltham, MA, USA). As a preconcentration step, peptides were loaded on a 2 cm 9 75 lm C18 Pepmap100 precolumn (Thermo Fisher Scientific) at a flow rate of 10 lLÁmin À1 using mobile phase A. Elution from the precolumn to a 50 cm 9 75 lm Pepmap100 analytical column (Thermo Fisher Scientific) and subsequent separation was achieved at a flow rate of 300 nLÁmin À1 using a gradient of 8% to 40% mobile phase B (80% ACN, 20% H 2 O, 0.1% formic acid) over 42 min. For mass spectrometric detection, MS scans were performed in the range from m/z 400-1400 at a resolution of 70 000 (at m/z = 200). MS/ MS scans of the eight most abundant ions were achieved through HCD fragmentation at 30% normalized collision energy and analyzed in the orbitrap at a resolution of 17 500 (at m/z = 200). Sequest included in PROTEOME DISCOVERER (version 1.4.0.288; Thermo Fisher Scientific) was applied as search algorithm in case of the modified FASTA database, otherwise MASCOT version 2.5.1 was used. A FDR < 0.01 for peptide spectrum matches was applied. Sequence coverage of recombinant FAM3C was determined by using the database for Mus musculus (Uniprot version 05/2017) supplemented with the sequence of proteolytically processed, 6xHis-tagged FAM3C. At the search for additional proteins in Band 3 (= 40 kDa band), bovine and human databases (Uniprot version 05/2017) were used and only FAM3C, but no other proteins were identified. S Protein Labeling Mix, NEN Radiochemicals; PerkinElmer, Waltham, MA, USA) for 120 min (pulse) to ensure that extracellular release of labeled proteins can be immediately monitored after pulse. Label was washed away and cells were incubated in the presence of unlabeled methionine and cysteine for additional 30, 60, or 120 min (chase) followed by Ni-NTA affinity capture of 6xHis-tagged ILEI from CM and whole-cell lysates of harvested cells. Samples were analyzed by autoradiography following SDS/PAGE and transfer to poly(vinylidene difluoride) (PVDF) membranes.
Pulse-chase analysis
Recombinant ILEI purification
Different forms of ILEI-6xHis were affinity purified using prepacked HisTrap excel 5 mL columns (GE Healthcare) from 2 to 3 L of CM of stably overexpressing HEK293 cells collected and pooled from confluent cultures of cells kept in the presence of 1% FCS. Purification was performed by FPLC on an € AKTA Start equipment (GE Healthcare) under native conditions using phosphate buffer (500 mM NaCl, 50 mM NaH 2 PO 4 , pH 6.0) supplemented with 5, 20, and 250 mM imidazole (pH 6.0) in the capturing, washing, and elution buffers, respectively. Elution fractions were tested for the presence of ILEI via western blot analysis. Positive fractions were pooled, concentrated, and buffer was exchanged to storage buffer (150 mM NaCl, 50 mM NaH 2 PO 4 , pH6.0) using Amicon ultrafiltration centrifugation units with a molecular cutoff of 10 kDa. ILEI concentrations of different purifications were normalized following total protein content measurement and protein detection by silver staining of SDS/ PAGE gels.
Size exclusion chromatography
For separation of purified dimers and monomers 25 lg of Ni-NTA purified wild-type ILEI-6xHis protein in 1 mL loading volume was separated on HiLoad 16/600 Superdex 75 pg SEC column (GE Healthcare) using a buffer composing 150 mM NaCl and 50 mM NaH 2 PO 4 , pH 6.0. Fractions of 3 mL were collected and tested for the presence of ILEI by western blot analysis. Two peaks of ILEI content were determined, corresponding fractions pooled, and concentrated as described in previous chapter. ILEI monomer and dimer separation was determined on nonreducing SDS/ PAGE. For dimer-monomer separation from CM of EpC40-WT, EpC40-CA, LM2-shILEI-WT reconst , and LM2-shILEI-CA reconst cells, 16 mL of 3-day CM were collected, exchanged to buffer with high ionic strength to eliminate all noncovalent protein interactions (500 mM NaCl, 50 mM NaH 2 PO4, pH 6.0) followed by concentration to 1 mL loading volume and separation on HiLoad 16/600 Superdex 75 pg SEC column (GE Healthcare) using a buffer composing 500 mM NaCl and 50 mM NaH 2 PO 4 , pH 6.0. About 3-mL fractions were collected and tested and quantified for the presence of ILEI by western blot analysis.
DTNB treatment
EpRas cells were seeded into six-well plates (500.000 cells/ well). Next day, fresh growth medium supplemented with DTNB in a final concentration of 2 mM or with same amount of solvent (0.5 M TRIS pH 7.4 in 50% DMSO) was added to the cells. CM were harvested 2, 4, and 8 h after treatment start. Timely changes in the alkylating capacity of cell culture media supplemented with DTNB were controlled by performing Ellman's assay [31] with the DTNB-containing CM using a dilution series of free Cysteine as substrate.
Trans-well invasion assay ) was added. Forty-eight hours after treatment start a scratch was introduced to the confluent cell layers, culture was switched to starvation medium containing the same factors as in the growth phase and wound closure was monitored by live-cell imaging for 20 h in 1-h time intervals using a Nikon Eclipse Ti inverted microscope (Life-Cell Imaging System compiled by Visitron Systems, Puchheim, Germany) under optimal cell culture conditions (37°C, 5% CO 2 , > 95% humidity) and a PCO Edge 4.2 sCMOS camera with a 209/0.5 Plan-Neofluar objective. Images were processed with VISIVIEW Software (Visitron Systems) and IMAGEJ followed by quantification in TSCRATCH software [37] .
Live-cell motion tracking
EpRas cells were seeded into chambered coverslip slides (Ibidi, Martinsried, Germany). Four hours after seeding, fresh medium supplemented with 4% FCS and purified wild-type (WT), dimerization-mutant (CA), SEC-purified ILEI monomers ( 
RNA isolation and real-time quantitative PCR
Total RNA was extracted from cells with RNeasy Plus kit according to the manufacturer's instructions (Qiagen, Venlo, the Netherlands). For cDNA synthesis, RNA was reverse-transcribed with ProtoScript II (New England Biolabs, Ipswich, MA, USA), then cDNA was amplified by real-time PCR with a Power SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA, USA) on an AbiPrism 7500 cycler (Applied Biosystems) using primers for the genes E-cadherin, claudin, occludin, N-cadherin, vimentin, fibronectin, Matrix Metallo Protease 9 (MMP9), twist, snail, slug, and zeb2. The data were quantified using the DDC t method, the expression of target genes was normalized to the expression of the housekeeping gene GAPDH.
Immunofluorescence
EpRas cells were fixed, permeabilized with 4% formaldehyde/0.1% TritonX-100, and immunostained after 48 h of treatment with empty vector preparation (ctrl), purified wild-type (WT), dimerization-mutant (CA), dimer or monomer ILEI using E-cadherin Quantification of lung metastatic colonization of EpC40 cells was performed by calculating the mean metastatic area of the lungs (%) AE SEM. Each lung was cut through serially in 3-lm-thick sections at 300-lm intervals, sections were stained with Hematoxylin and Eosin (H&E) and scanned (Mirax scanner; Zeiss). Absolute value of metastatic and total lung area of each section was determined by a semi-automated analysis workflow developed and executed in the DEFINIENS DEVELOPER XD software (version 2.4.2; Definiens AG, Munich, Germany). Briefly, lung tissue area was first separated from background, then regions of healthy tissue were defined according to structural properties and used as an internal standard to set threshold values for subsequent tumor detection. Tumor tissue was automatically defined based on spectral properties followed by a manual correction step for final tissue classification and subsequent calculation of tissue areas. The percentage of metastatic lung area per mouse was calculated from the sum of metastatic and total lung areas of all sections of each lung.
Immunohistochemistry
Immunohistochemistry on paraformaldehyde fixed, paraffin embedded, 3-lm-thick sections of mouse tumor tissues was performed manually using anti-FLAG (1 : 300; Sigma) anti-ILEI (1 : 500) [14] , anti-E-cadherin (1 : 1000; BD Biosciences), and anti-vimentin (1 : 500; Sigma) primary antibodies and Lab Vision TM UltraVision TM LP Detection System (Thermo Fisher Scientific) with 2,4-diaminobutyric acid substrate (Agilent Technologies, Santa Clara, CA, USA) for detection according to the manufacturer's instruction. Cell nuclei were visualized by hematoxylin staining. Images were taken by a Nikon Eclypse 80i microscope (Nikon, Tokyo, Japan).
Statistical analysis
Data are expressed as the mean AE SEM where applicable. Statistical significance was determined by unpaired twosided Student's t-test and one-way or two-way ANOVA tests. P < 0.05 was considered significant and marked with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001). 
